Kornimate/medical-research-clean huggingface dataset:
antiphospholipid antibodies and early severe preeclampsia.

Conditions: Severe Preeclampsia; Antiphospholipid Syndrome

Summary: the antiphospholipid syndrome is an immune disease where the presence of antibodies directed against cell membrane phospholipids (antiphospholipid antibodies) can cause an hypercoagulable state that causes thrombosis and obstetric complications (miscarriages, stillbirths). since 1999 the sapporo criteria for antiphospholipid syndrome diagnosis includes the development of severe preeclampsia before 34 weeks of gestation, but this was done without solid evidence of a relation between the two. our study will try to add information to this particular point.


Eligibility criteria:
inclusion criteria: * gestational age between 24-34 weeks * diagnosis of severe preeclampsia exclusion criteria: * known antiphospholipid syndrome. * known presence of antiphospholipid antibodies. * patients with systemic lupus erythematosus.

Keywords: antibodies, anticardiolipin antibodies, b2 glycoprotein i lupus anticoagulant severe preeclampsia
study of the effects of iron on lung blood pressure at high altitude

Conditions: Hypertension, Pulmonary

Summary: body iron levels may be important in determining how the blood pressure in the lungs changes in response to low oxygen levels. at high altitude, where oxygen levels are low, some patients develop elevated lung blood pressure. the investigators hypothesize that, in high altitude residents with elevated lung blood pressure, iron supplementation will cause a reduction in lung blood pressure.

pulmonary hypertensive disorders frequently complicate hypoxic lung disease and worsen patient survival. hypoxia-induced pulmonary hypertension is also a major cause of morbidity at high altitude. hypoxia causes pulmonary hypertension through hypoxic pulmonary vasoconstriction and vascular remodelling. these processes are thought to be regulated at least in part by the hypoxia-inducible factor (hif) family of transcription factors, which coordinate intracellular responses to hypoxia throughout the body. hif is regulated through a cellular degradation process that requires iron as an obligate cofactor. in cultured cells hif degradation is inhibited by reduced iron availability (by chelation with desferrioxamine) and potentiated by iron supplementation. in humans, laboratory experiments lasting eight hours have shown that acute iron supplementation blunts the pulmonary vascular response to hypoxia, while acute iron chelation with desferrioxamine enhances the response. these findings suggest that iron may also affect the pulmonary vascular response to hypoxia over longer time periods. the purpose of this study, which will take place at high altitude in kyrgyzstan, is to investigate whether iron supplementation can reduce pulmonary artery pressure in patients with established high altitude pulmonary hypertension.

Eligibility criteria:
inclusion criteria: * high altitude natives, currently resident at high altitude * pulmonary hypertension (mean pulmonary artery pressure \> 25 mmhg) * pulmonary artery systolic pressure measurable using doppler echocardiography exclusion criteria: * clinical evidence or history of major co-morbidity * recent changes to relevant medications, or taking iron/vitamin supplements

Keywords: pulmonary artery pressure hypoxia iron hypoxia-inducible factor high altitude
reducing overdose after release from incarceration

Conditions: Overdose, Drug

Summary: the primary objective of the roar project is to evaluate an oregon department of corrections (odoc) pilot program that combines the use of extended-release naltrexone (xr-ntx) and certified recovery mentors pre-release with linkage to community substance use disorder treatment to prevent fatal and non-fatal opioid overdoses among female adults released from prison.

roar examines implementation of a novel overdose prevention strategy for justice-involved women as they re-enter community treatment settings after incarceration. the odoc pilot project offers initiation of opioid antagonist treatment prior to release (extended-release naltrexone \[xr-ntx\]), ongoing support from a certified recovery mentor (crm), and facilitated entry into community treatment for substance use disorders. community treatment may include continuation of xr-ntx,or transition to agonist therapy including buprenorphine or methadone, or no medication for opioid use disorder.

Eligibility criteria:
inclusion criteria: * be a woman (including transgender and non-binary adults assigned to women's housing at cccf) * 18 years of age or older with a known release date during the 18-month recruitment period * be released to marion, multnomah, clackamas or washington county, oregon * be willing and able to provide informed consent and hipaa authorization for medical record abstraction and linkage to state administrative data * meet dsm-v (diagnostic and statistical manual) criteria for moderate or severe opioid use disorder * be willing to establish ongoing care at the community sud (substance use disorder) treatment site in county of release * be willing to initiate xr-ntx prior to release from incarceration * not be currently pregnant and must be willing to take at least one evidence-based measure to avoid becoming pregnant during treatment with xr-ntx exclusion criteria: a participant will be excluded if she * has a severe medical, psychiatric, or substance use disorder that, in the opinion of the cccf qualified mental health professional (qmhp)or study physician, would make study participation hazardous to the participant, compromise study findings, or prevent the participant from completing the study due to imminent risk of death * has another medical condition leading xr-ntx to be contraindicated * has chronic pain requiring ongoing pain management with opioid analgesics * received methadone or buprenorphine maintenance therapy in the 4 weeks prior to consent * has a planned surgery or other procedure within the next 4 weeks that will require opioid analgesia
retrospective medical record review of mind body depression group participants

Conditions: Depression; Anxiety

Summary: the purpose of this study is to assess the effectiveness of a relaxation response intervention for depression offered to low income populations at massachusetts general hospital (mgh) - chelsea, revere and charlestown health centers.

this is a retrospective review of medical records. the study aims to evaluate the effects of participation in the relaxation response intervention for depression clinical groups, on patient measures of: 1) depression, anxiety and perceived stress; 2) work productivity and activity impairment; 3) demand for, and adherence to behavioral medicine; 4) medication use for depression and/or anxiety; and 5) dose-response effects.

Eligibility criteria:
inclusion criteria: * patients receiving care through mgh-health centers * a diagnosis of depression and/or anxiety * 21 years of age or older exclusion criteria: -
myasthenia gravis registry in china

Conditions: Myasthenia Gravis

Summary: myasthenia gravis (mg) is an autoimmune disease caused by dysfunction at the neuromuscular junction, characterized by partial or generalized skeletal muscle weakness and fatigability. the estimated annual incidence rate of mg in china is 0.68/100,000, with a high rate of relapse and poor treatment compliance. this study is a prospective, observational, multi-center patient registry across china. to support standardized management and follow-up of mg patients in china, a cloud-based mg patient management platform (cn mg base) was established in september 2023 with the support of the chinese rare diseases alliance. the platform aims to collect longitudinal clinical data including demographic information, age of onset, medical history, comorbidities, medication usage, treatment responses, and others. it is intended to collect newly registered mg cases each year and follow up with these patients at one-year intervals for ten years

this study is a observational nationwide multicenter mg registry research. starting from the baseline, annual follow-ups will be conducted to prospectively collect information on treatment medications, prognosis, and safety events. the following classification definitions can be applied: ① mg clinical subtypes (ocular, early-onset generalized, thymoma-related, late-onset generalized, musk-related, and seronegative); ② different treatment methods (classic immunotherapy group, b-cell-targeted therapy, complement inhibition therapy, rapid-acting therapy, and il-6 pathway inhibitors, etc.).

Eligibility criteria:
inclusion criteria: * fluctuating weakness in skeletal muscles, such as extraocular, bulbar, limb muscles, etc.. demonstrating fluctuation and fatigability: weakness is usually worse in the morning and improves with rest; worsens with sustained activity. * patients themselves or their guardians can understand and sign the informed consent form. to meet the eligibility criteria, at least one of the following additional criteria must be met: * a. positive tensilon test; * b. decrease in compound muscle action potential by more than 10% with low-frequency repetitive nerve stimulation or widening of the "jitter" (the variability in time of the second action potential relative to the first) on single-fiber electromyography, with or without blocking; * c. positive antibodies: serum testing positive for achr antibodies, musk antibodies, or lrp4 antibodies. exclusion criteria: * patients with mental illness who cannot cooperate. * patients with multiple organ dysfunction or in extremely critical condition, unable to complete relevant medical history collection or evaluation.

Keywords: myasthenia gravis prospective study observational study patient registry
observational peripheral iv insertion study

Conditions: Pain, Acute; Satisfaction

Summary: iv placement is a common and necessary for surgical procedures. unfortunately, pain associated with needle catheterization experienced during peripheral iv placement is a source anxiety and discomfort in many patients. the intensity of pain and distress caused by procedures can vary from mild to moderate, but also may be severe in certain patients resulting in numerous physiological, psychological, and emotional consequences. as such, the investigators ultimately aim to evaluate the techniques that could make the placement of the iv more comfortable.

as a preliminary study, the investigators are interested in conducting a prospective observational study to collect baseline data to characterize and collect baseline data on pain associated with needle catheterization in the hospital. many factors including size of needle, experience of the individual placing iv, previous history of depression may vary the iv placement experience of a patient; however, only some of these factors may directly affect the magnitude of pain experienced by a patient. currently, there is limited literature available on what factors affect the pain/satisfaction patients experience with iv insertion. soysal et al. have previously reported that depressed patients reported higher severity of pain during iv catheter placement than non-depressed patients in a cross-sectional, observational study (n= 925). the authors have also demonstrated that age, sex, site of iv catheter insertion, use of antidepressant drugs, and whether the individual placing the iv catheter is a nurse or physician do not affect the magnitude of pain. similarly, van loon et al have demonstrated that insertion of a smaller sized peripheral intravenous catheter did not result in lower pain sensation. however, galvin et al. conducted a randomized clinical trial that demonstrated that the site of iv catheter insertion makes a difference in the pain patients feel during iv catheter insertion. furthermore, no study exists that has investigated whether patients experience a different magnitude of pain when different levels of physician trainees place the iv catheter. also, no study exists that compares whether peripheral iv cannulation with no pain relief method versus intradermal lidocaine 1% injection versus intradermal lidocaine 2% injection versus buzzy® device affect the pain/satisfaction that patients experience with iv catheter insertion. through the conduction of this study, the investigators hope to further evaluate which factors and techniques affect the experience patients have with peripheral iv cannulation; this knowledge could help the investigators figure out ways to make iv cannulation as comfortable as possible for patients in the future.

Eligibility criteria:
inclusion criteria: * adults ages 18 to 99 * patients requiring intravenous catheter insertion for their operation/procedure. exclusion criteria: -
imaging methods for the diagnosis of non-melanoma skin cancer and its precursors

Conditions: Non-melanoma Skin Cancer

Summary: prospective, unicentric study that examines if imaging devices like total body photography, dermoscopy, optical coherence tomography and in vivo reflectance confocal microscopy as an addition to clinical examination lead to a benefit for patients in the diagnosis of non-melanoma skin cancer and their precursors

250 patients with lesions that are suspicious for non-melanoma skin cancer that had not yet had a biopsy, are randomized in 2 groups. the intervention group is examined with total body photography, dermoscopy, optical coherence tomography and in vivo reflectance confocal microscopy; the control group is examined with dermoscopy only. the aim of the study is to investigate whether these methods improve the early detection of non-melanoma skin cancer and their precursors. examined are not only the differences in management of the lesions (excision, biopsy, local treatment or no treatment) and the diagnostic accuracy of the devices.

Eligibility criteria:
inclusion criteria: * patients with 1 or more lesions suspicious for non-melanoma skin cancer that had not yet had a biopsy or diagnostic excision of the lesions exclusion criteria: * patients with non-melanoma skin cancer that has already been examined with a punch biopsy or diagnostic excision * patients younger than 18 years * patients that are incapable of giving consent

Keywords: dermoscopy 3d total body photography optical coherence tomography in vivo reflectance confocal microscopy total body photography non-invasive imaging confocal microscopy
robot-assisted laparoscopic hysterectomy-ralh- postoperative complications, quality of life and health economics

Conditions: Endometrial Cancer; Treatment by Robotic Assisted Laparoscopy Hysterectomy

Summary: the propose of this study is to describe recovery and experience of pain and health related quality of life after robot-assisted laparoscopic hysterectomy for women with endometrial cancer or atypical complex hyperplasia.


Eligibility criteria:
inclusion criteria: women suspected of having endometrial cancer or having atypical complex hyperplasia * ability to understand and speak danish * ability to cooperate * provision of written informed consent exclusion criteria: * having a benign condition after histopathology postoperatively * bing assigned to radiation or chemotherapy postoperatively

Keywords: endometrial cancer (mesh) robotics (mesh)
persistence of antibody responses among children who previously received novartis menacwy conjugate vaccine or meningococcal c conjugate vaccine

Conditions: Meningococcal Disease

Summary: the primary purpose of this study is to evaluate the persistence of bactericidal antibodies in children of approximately 22 to 45 months of age previously enrolled in the v59p22 study (nct00667602) who received novartis menacwy conjugate vaccine or meningococcal c conjugate vaccine. this is measured by percentage of subjects with human serum bactericidal assay (hsba) titers ≥ 1:8 directed against neisseria meningitidis serogroups a, c, w-135, and y. in addition the response one month post an additional dose of novartis menacwy will be measured by percentage of subjects with hsba titers ≥ 1:8 and gmts.


Eligibility criteria:
inclusion criteria: children eligible to be enrolled in the study were those * whose parents provide written informed consent; * were in generally good health based on the clinical judgment of the investigators; * subjects were 22-45 months of age at the time of enrollment into v59p22e1; * subject who had participated in the parent v59p22 study. exclusion criteria: main exclusion criteria: * subjects with serious, acute, or chronic illnesses * subjects who had received any other licensed vaccines within 28 days (exception: influenza vaccine was allowed up to 14 days prior to and no less than 14 days after the study immunization) prior to enrolment and any study visit * subjects who had received any meningococcal vaccine since the study dose of menacwy or men c at 12 months of age in v59p22 trial.

Keywords: meningococcal acwy conjugate vaccine meningitis toddlers children persistence boost
a study evaluation the safety and efficacy of hormone replacement therapy with north star compared to levothyroxine in patients with primary hypothyroidism

Conditions: Hypothyroidism

Summary: the north star study is a multi-center, phase 2, double-blind, randomized, parallel group clinical study to evaluate the safe and effective dose conversion from levothyroxine to north star therapy.


Eligibility criteria:
inclusion criteria: * diagnosed with primary hypothyroidism * on continuous thyroid replacement therapy for at least 6 months before study entry * on a stable daily dose of lt4 for a minimum of 12 weeks prior to screening * agree to practice a method of contraception * female patients not pregnant or lactating at screening * agree to practice a method of contraception of greater than 90% reliability * willing to give written informed consent for the study * provide written authorization for use and disclosure of protected health information exclusion criteria: * any clinical condition or previous surgery that might affect the absorption, distribution, biotransformation or excretion of north star or levothyroxine * hospitalization for a major illness within 4 weeks prior to screening * anticipated initiation or change in concomitant medications * concomitant use of prohibited medications or supplements * participated in another investigational new drug study within 30 days or 5 half-lives of the imp, whichever is longer, prior to the first study drug administration. * for female subjects, be pregnant, nursing or planning to become pregnant during the study
hot and cold compress in hemodialysis

Conditions: Hemodialysis Complication; Muscle Spasm; Fatigue

Summary: aims and objectives. to examine and compare the effects of hot and cold compresses administration on muscle cramps, fatigue, and comfort in hemodialysis (hd) patients. background. muscle cramps and fatigue are common complications in hd patients and reduce patient comfort. among the nursing interventions stated for the management of these complications in the literature, hot and cold therapy are remarkable. to the best of our knowledge, the present study is the first research up to date that examined and compared the effects of hot and cold compress administrations on abovementioned complications in hd. design. this placebo-controlled randomized trial was conducted in two hemodialysis centers between february and october 2020. methods. the study sample consisted of 69 patients, stratified and randomly allocated to two intervention groups and placebo group. for patients of each group, the implementation of the study continued for four weeks, 12 hd sessions.

hemodialysis (hd) is a common renal replacement therapy used in the treatment of end-stage renal disease (esrd) worldwide. although hd is a life-saving treatment for people with esrd, it causes some acute and chronic complications. muscle cramps and fatigue are two of the most common complications in hd, and these also cause reducing comfort. management of complications in hd patients and ensuring an optimal comfort level are pivotal for nurses. according to the literature, recommended nursing practices for the management of cramps in hd patients include hot and cold therapy methods. besides, preventing cramps can improve comfort by reducing fatigue. therefore, this study aimed to examine and compare the effects of hot and cold compresses administration on muscle cramps, fatigue, and comfort in hemodialysis (hd) patients.

Eligibility criteria:
inclusion criteria: * between the ages of 18-65, * receiving hd treatment for at least six months, * three days a week with four-hour sessions * with blood pressure 120/80 mmhg and higher at the beginning of the hd session, * did not develop intradialytic hypotension in the first two hours of hd, * hemoglobin value above 8.0 mg/dl, * having a stable dry weight for the previous month (less than 2 kg change). exclusion criteria: * receiving intravenous electrolyte replacement during hd session, * having a condition that prevented hot or cold administration such as diabetic neuropathy, burns, open wounds, and amputation in the lower extremities, * with an oncological diagnosis or autoimmune disease (rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, fibromyalgia, etc.), * refused to participate in the study

Keywords: hemodialysis muscle cramp fatigue comfort nursing care complementary therapies
evaluate the safety and efficacy of cd33 car-t in patients with r/r aml

Conditions: AML

Summary: this is an open label, phase i study to assess the safety and efficacy of cd33 car-t in patients with relapsed and refractory acute myeloid leukemia


Eligibility criteria:
inclusion criteria: 1. all subjects must sign and date the informed consent before initiating any study specific procedures or activities; 2. diagnosed as relapse/refractory (r/r) de novo or secondary acute myeloid leukemia (aml); 3. the expression of cd33 in aml blast is positive ; 4. the patient has recovered from the toxicity of previous treatment; 5. ecog score ≤ 2 and expected survival period is not less than 3 months; 6. adequate organ function defined as: ast ≤3×uln; alt ≤3×uln; total bilirubin ≤1.5×uln; serum creatinine ≤1.5×uln, or ccr≥60 ml/min; hemoglobin ≥60g/l ; indoor oxygen saturation ≥92%; lvef≥45%; 7. pregnancy testing: females of childbearing potential must have a negative serum or urine pregnancy test; 8. from the use of study drug to 2 years after treatment, males and female of childbearing potential must agree to use an effective method of contraception exclusion criteria: 1. diagnosis of acute promyelocytic leukemia; 2. history or presence of a cns disorder; 3. hbsag or hbcab are positive; hcv 、hiv and syphilis antibody are positive, cmv dna in peripheral blood is more than≥500 copies /ml; 4. history of severe hypersensitivity reaction; 5. history of myocardial infarction, cardiac angioplasty or stenting, unstable angina, new york heart association class ii or greater congestive heart failure, atrial fibrillation, or other clinically significant cardiac disease within 12 months before enrollment; 6. history of organ transplant surgery; 7. required systemic application of immunosuppressive or other drugs; 8. auto-sct within the 3 months before enrollment; 9. active autoimmune or inflammatory diseases of the nervous system (e.g., guillain-barre syndrome (gbs), amyotrophic lateral sclerosis (als)) and clinically active cerebrovascular diseases (e.g., cerebral edema, posterior reversible encephalopathy syndrome (pres)); 10. requirement for urgent therapy due to ongoing or impending oncologic emergency (eg, leukostasis or tumor lysis syndrome (tls)) ; 11. presence or suspicion of a fungal, bacterial, viral, or other infection that is uncontrolled or requiring antimicrobials for management; 12. live vaccine received within the ≤ 4 weeks before enrollment; 13. persons with serious mental illness; 14. history of major surgical operations four weeks before enrollment; 15. history of alcoholism or substance abuse; 16. was identified by the investigators as unsuitable to participate in the study